Dissolved Oxygen Dressing to Improve Chronic Wound Healing After Revascularization for Critical Limb Ischemia
Primary Purpose
Critical Limb Ischemia
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Oxygenesys(TM) Dissolved Oxygen Dressing
Sponsored by

About this trial
This is an interventional treatment trial for Critical Limb Ischemia focused on measuring Critical Limb Ischemia, Non Healing Wounds, Diabetic Wounds, Foot Ulcers
Eligibility Criteria
Inclusion Criteria:
- Male or non-pregnant female >=21 years of age
- A clinical diagnosis of critical limb ischemia (CLI) with Rutherford classification stage 5
- One or more chronic ulcers with a presumed etiology of arterial insufficiency and duration >2 weeks. The target ulcer is defined as the highest-grade ulcer (Wagner's classification) at initial evaluation. For wounds with identical grading, the largest wound is the index wound
- The patient or legally authorized representative is willing to provide informed consent and comply with specified follow-up evaluations
- Undergoing intervention for infrainguinal or infrapopliteal artery disease (below the femoral artery bifurcation and above the ankle joint)
- The index procedure resulted in successful revascularization. For endovascular procedures, successful revascularization is defined as complete revascularization of the target ulcer culprit vessels according to the angiosome treatment strategy, with a final percent diameter stenosis >50% and improved distal flow by angiography following the procedure. For surgical procedures, successful revascularization is defined as a patent graft and improved distal flow following the procedure.
Exclusion Criteria:
- Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year following index procedure. Female patients of child-bearing potential must have a negative pregnancy test done within 7 days prior to index procedure.
- Rutherford classification stage 0,1,2,3,4, or 6
- Target wound duration <2 weeks
- Presence of frank gangrene (Wagner classification grade 4 or 5), major tissue loss (severe/extensive necrosis), or unsalvageable limb (extensive ischemic ulceration beyond the transmetatarsal level anticipated to require major amputation after the index procedure)
- Previous or planned surgical or interventional procedure within 6 months before or 30 days after the index procedure, or any previous or planned target limb amputation.
- Active local or systemic infection
- Patients with ulcers judged by the examining physician to have a primary etiology other than ischemic arterial disease (e.g., venous related, decubitus, or other [goug, pyoderma gangrenosum, necrobiosis lipoidica, vitamin B12 deficiency])
- Renal failure or chronic kidney disease with estimated glomerular filtration rate (eGFR <30 ml/min/1.7sm sq. within 30 days of the index procedure or treated with dialysis)
- Severly decreased cardiac output
- Uncontrolled hyperglycemia
- Patients with a known other medical illness or known history of substance abuse that may cause non-compliance with the protocol, confound data interpretation, or is associated with a life expectancy of less than 1 year
- Patient is currently participating (or has participated in the last 30 days) in a study of any other investigational treatment.
- Ulcer treatment with normothermic or hyperbaric oxygen therapy, recombinant or autologous growth factor products, or use of enzymatic debridement
- Concomitant medications such as corticosteroids, immunosuppressive medications, or chemotherapy
- Acute thrombus in the target limb
Sites / Locations
- Yale New Haven Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
OxyGenesys(TM) Dissolved Oxygen Dressing
Standard Wound Care
Arm Description
OxyGenesys(TM) Dissolved Oxygen Dressing
Standard wound care using gauze dressings per institutional standard of care.
Outcomes
Primary Outcome Measures
Rate of Wound Healing
Percentage reduction in target wound area (length x width).
Secondary Outcome Measures
Incidence of Complete Wound Closure
number of wounds undergoing complete reepithelialization without drainage or dressing requirements, maintained for at least 2 weeks.
Full Information
NCT ID
NCT02046226
First Posted
January 23, 2014
Last Updated
October 8, 2015
Sponsor
Halyard Health
Collaborators
Yale University
1. Study Identification
Unique Protocol Identification Number
NCT02046226
Brief Title
Dissolved Oxygen Dressing to Improve Chronic Wound Healing After Revascularization for Critical Limb Ischemia
Official Title
A Prospective, Randomized, Single-center Pilot Study of the OxyGenesys™ Dissolved Oxygen Dressing to Improve Chronic Wound Healing After Revascularization for Critical Limb Ischemia
Study Type
Interventional
2. Study Status
Record Verification Date
November 2014
Overall Recruitment Status
Terminated
Why Stopped
inability to meet enrollment goals in this subject population
Study Start Date
August 2013 (undefined)
Primary Completion Date
May 2014 (Actual)
Study Completion Date
May 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Halyard Health
Collaborators
Yale University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
A Prospective, Randomized, Single-center Pilot Study of The OxyGenesys(TM) Dissolved Oxygen Dressing to Improve Chronic Wound Healing after REvascularization for Critical Limb Ischemia.
Detailed Description
A Prospective, Randomized, controlled pilot study enrolling up to 50 subjects at a singe investigational site in the US. Subjects with atherosclerotic peripheral arteria disease (PAD) presenting with critical limb ischemia (CLI) and one or more non-healing lower extremity arterial insufficiency ulcers who are suitable candidates for revascularization procedures (endovascular or surgical) will be randomized 1:1 to:
Wound care with the use of OxyGenesys(TM) Dissolved Oxygen Dressing, or
Standard Wound Care procedures
An initial study phase will enroll up to 20 subjects (10 in each arm). Pending results of the initial study phase, the study may continue to enroll until up to 50 subjects (25 in each arm) have been enrolled.
All subjects will be followed clinically and receive wound evaluation at 1, 3, and 6 months.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Critical Limb Ischemia
Keywords
Critical Limb Ischemia, Non Healing Wounds, Diabetic Wounds, Foot Ulcers
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
7 (Actual)
8. Arms, Groups, and Interventions
Arm Title
OxyGenesys(TM) Dissolved Oxygen Dressing
Arm Type
Experimental
Arm Description
OxyGenesys(TM) Dissolved Oxygen Dressing
Arm Title
Standard Wound Care
Arm Type
No Intervention
Arm Description
Standard wound care using gauze dressings per institutional standard of care.
Intervention Type
Device
Intervention Name(s)
Oxygenesys(TM) Dissolved Oxygen Dressing
Intervention Description
OxyGenesys(TM) Dissolved Oxygen Dressing
Primary Outcome Measure Information:
Title
Rate of Wound Healing
Description
Percentage reduction in target wound area (length x width).
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Incidence of Complete Wound Closure
Description
number of wounds undergoing complete reepithelialization without drainage or dressing requirements, maintained for at least 2 weeks.
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or non-pregnant female >=21 years of age
A clinical diagnosis of critical limb ischemia (CLI) with Rutherford classification stage 5
One or more chronic ulcers with a presumed etiology of arterial insufficiency and duration >2 weeks. The target ulcer is defined as the highest-grade ulcer (Wagner's classification) at initial evaluation. For wounds with identical grading, the largest wound is the index wound
The patient or legally authorized representative is willing to provide informed consent and comply with specified follow-up evaluations
Undergoing intervention for infrainguinal or infrapopliteal artery disease (below the femoral artery bifurcation and above the ankle joint)
The index procedure resulted in successful revascularization. For endovascular procedures, successful revascularization is defined as complete revascularization of the target ulcer culprit vessels according to the angiosome treatment strategy, with a final percent diameter stenosis >50% and improved distal flow by angiography following the procedure. For surgical procedures, successful revascularization is defined as a patent graft and improved distal flow following the procedure.
Exclusion Criteria:
Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year following index procedure. Female patients of child-bearing potential must have a negative pregnancy test done within 7 days prior to index procedure.
Rutherford classification stage 0,1,2,3,4, or 6
Target wound duration <2 weeks
Presence of frank gangrene (Wagner classification grade 4 or 5), major tissue loss (severe/extensive necrosis), or unsalvageable limb (extensive ischemic ulceration beyond the transmetatarsal level anticipated to require major amputation after the index procedure)
Previous or planned surgical or interventional procedure within 6 months before or 30 days after the index procedure, or any previous or planned target limb amputation.
Active local or systemic infection
Patients with ulcers judged by the examining physician to have a primary etiology other than ischemic arterial disease (e.g., venous related, decubitus, or other [goug, pyoderma gangrenosum, necrobiosis lipoidica, vitamin B12 deficiency])
Renal failure or chronic kidney disease with estimated glomerular filtration rate (eGFR <30 ml/min/1.7sm sq. within 30 days of the index procedure or treated with dialysis)
Severly decreased cardiac output
Uncontrolled hyperglycemia
Patients with a known other medical illness or known history of substance abuse that may cause non-compliance with the protocol, confound data interpretation, or is associated with a life expectancy of less than 1 year
Patient is currently participating (or has participated in the last 30 days) in a study of any other investigational treatment.
Ulcer treatment with normothermic or hyperbaric oxygen therapy, recombinant or autologous growth factor products, or use of enzymatic debridement
Concomitant medications such as corticosteroids, immunosuppressive medications, or chemotherapy
Acute thrombus in the target limb
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carlos Mena-Hurtado, MD
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
David T Curd, MS
Organizational Affiliation
Kimberly-Clark Corporation
Official's Role
Study Director
Facility Information:
Facility Name
Yale New Haven Hospital
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06510
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Dissolved Oxygen Dressing to Improve Chronic Wound Healing After Revascularization for Critical Limb Ischemia
We'll reach out to this number within 24 hrs